Log in

Relevant bibliographies by topics / Urotensin II / Journal articles

To see the other types of publications on this topic, follow the link: Urotensin II.

Journal articles on the topic 'Urotensin II'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Urotensin II.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Giuliani, Luisa, Livia Lenzini, Michele Antonello, et al. "Expression and Functional Role of Urotensin-II and Its Receptor in the Adrenal Cortex and Medulla: Novel Insights for the Pathophysiology of Primary Aldosteronism." Journal of Clinical Endocrinology & Metabolism 94, no. 2 (2009): 684–90. http://dx.doi.org/10.1210/jc.2008-1131.

Full text

Abstract:

Abstract Context: The involvement of urotensin II, a vasoactive peptide acting via the G protein-coupled urotensin II receptor, in arterial hypertension remains contentious. Objective: We investigated the expression of urotensin II and urotensin II receptor in adrenocortical and adrenomedullary tumors and the functional effects of urotensin II receptor activation. Design: The expression of urotensin II and urotensin II receptor was measured by real time RT-PCR in aldosterone-producing adenoma (n = 22) and pheochromocytoma (n = 10), using histologically normal adrenocortical (n = 6) and normal

APA, Harvard, Vancouver, ISO, and other styles

2

Desai, Nirav, Jameel Sajjad, and William H. Frishman. "Urotensin II." Cardiology in Review 16, no. 3 (2008): 142–53. http://dx.doi.org/10.1097/crd.0b013e31815c8048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Giebing, G., M. Tölle, S. Schmidt, A. Oksche, W. Zidek, and M. Van Der Giet. "UROTENSIN II-RECEPTORS SHOW RAPID DESENSITIZATION AFTER STIMULATION WITH UROTENSIN II." Journal of Hypertension 22, Suppl. 2 (2004): S48. http://dx.doi.org/10.1097/00004872-200406002-00161.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Dubessy, Christophe, Dorthe Cartier, Benoît Lectez, et al. "Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction." Journal of Neurochemistry 107, no. 2 (2008): 361–74. http://dx.doi.org/10.1111/j.1471-4159.2008.05624.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lafta, Israa A., Nahla A. AL-Bakri, and Wasan A. Abdulhameed. "Expression of Urotensin II of Human Placental Tissues and in Serum in Gestational Diabetic Mellitus in Iraqi Woman." INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY 12, no. 01 (2022): 70–73. http://dx.doi.org/10.25258/ijddt.12.1.13.

Full text

Abstract:

The placenta is an organ between the mother and fetus necessary for fetal growth and development. Gestational diabetes mellitus (DM) is the most frequent metabolic condition detected during pregnancy. It is characterized as hyperglycemia of various severity with onset or first detection during pregnancy that does not clearly describe any form of preexisting diabetes. Urotensin II (UII), a pluripotent vasoactive peptide, is important in developing insulin resistance. This study aimed to determine the level of Urotensin II(UII) in placenta and in the serum of diabetic and nondiabetic women. Meth

APA, Harvard, Vancouver, ISO, and other styles

6

Itoh, H., and K. Lederis. "Relationship of urotensin I induced vasodilatory action in rat thoracic aorta to Ca2+ regulation." Canadian Journal of Physiology and Pharmacology 65, no. 3 (1987): 298–302. http://dx.doi.org/10.1139/y87-052.

Full text

Abstract:

The relaxant effects of the synthetic fish neuropeptide urotensin I were examined in helical strips of rat aorta. In K+-depolarized aorta strips, urotensin I and verapamil competitively inhibited Ca2+-induced contractions. Urotensin I relaxed, in a concentration-dependent manner, the contraction produced by the Ca2+ ionophore A23187, whereas verapamil had no effect on this contraction, even at a concentration of 10−5 M. In the absence and presence of extracellular Ca2+, urotensin I inhibited both components of the contractions elicited by norepinephrine or urotensin II, another fish neuropepti

APA, Harvard, Vancouver, ISO, and other styles

7

Strack, Martin, Étienne Billard, David Chatenet, and William D. Lubell. "Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II." Bioorganic & Medicinal Chemistry Letters 27, no. 15 (2017): 3412–16. http://dx.doi.org/10.1016/j.bmcl.2017.05.088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Carotenuto, A., P. Grieco, P. Rovero, and E. Novellino. "Urotensin-II Receptor Antagonists." Current Medicinal Chemistry 13, no. 3 (2006): 267–75. http://dx.doi.org/10.2174/092986706775476061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Loirand, Gervaise, Malvyne Rolli-Derkinderen, and Pierre Pacaud. "Urotensin II and atherosclerosis." Peptides 29, no. 5 (2008): 778–82. http://dx.doi.org/10.1016/j.peptides.2007.08.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hazon, N., C. Bjenning, and J. M. Conlon. "Cardiovascular actions of dogfish urotensin II in the dogfish Scyliorhinus canicula." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 265, no. 3 (1993): R573—R576. http://dx.doi.org/10.1152/ajpregu.1993.265.3.r573.

Full text

Abstract:

Bolus injections of synthetic dogfish urotensin II (0.1-1.0 nmol) into the celiac artery of the conscious dogfish Scyliorhinus canicula (n = 8) resulted in sustained and dose-dependent increases in arterial blood pressure and pulse pressure. A maximum rise in mean arterial pressure of 10.5 +/- 1.2 mmHg (equivalent to 38.6 +/- 4.2% over mean basal values) and a maximum increase in pulse pressure of 3.9 +/- 0.8 mmHg was elicited by injection of 0.5 nmol of peptide. In comparison, a bolus injection of epinephrine (5 nmol) elicited a rise of 24.8 +/- 3.3% in mean arterial pressure. Bolus injection

APA, Harvard, Vancouver, ISO, and other styles

11

Merlino, Francesco, Salvatore Di Maro, Ali Munaim Yousif, Michele Caraglia, and Paolo Grieco. "Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures." Journal of Amino Acids 2013 (February 25, 2013): 1–15. http://dx.doi.org/10.1155/2013/979016.

Full text

Abstract:

Urotensin-II was originally isolated from the goby urophysis in the 1960s as a vasoactive peptide with a prominent role in cardiovascular homeostasis. The identification of human isoform of urotensin-II and its specific UT receptor by Ames et al. in 1999 led to investigating the putative role of the interaction U-II/UT receptor in multiple pathophysiological effects in humans. Since urotensin-II is widely expressed in several peripheral tissues including cardiovascular system, the design and development of novel urotensin-II analogues can improve knowledge about structure-activity relationship

APA, Harvard, Vancouver, ISO, and other styles

12

Langham, Robyn G., Darren J. Kelly, Renae M. Gow, et al. "Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy." American Journal of Kidney Diseases 44, no. 5 (2004): 826–31. http://dx.doi.org/10.1016/s0272-6386(04)01130-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Prosser, H. C. G., M. E. Forster, A. M. Richards, and C. J. Pemberton. "Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury." Peptides 29, no. 5 (2008): 770–77. http://dx.doi.org/10.1016/j.peptides.2007.08.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Russell, Fraser. "Urotensin II in cardiovascular regulation." Vascular Health and Risk Management Volume 4 (August 2008): 775–85. http://dx.doi.org/10.2147/vhrm.s1983.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Sun, Shui-lin, and Liang-ming Liu. "Urotensin II: an inflammatory cytokine." Journal of Endocrinology 240, no. 3 (2019): R107—R117. http://dx.doi.org/10.1530/joe-18-0505.

Full text

Abstract:

Urotensin II (UII) is a polypeptide molecule with neurohormone-like activity. It has been confirmed that UII is widely distributed in numerous organs of different animal species from fish to mammals, including humans. The UII receptor is orphan G-protein-coupled receptor 14, also known as UT. The tissue distribution of UII and UT is highly consistent, and their expression may be regulated by autocrine and paracrine mechanisms. In the body, UII has many physiological and pathophysiological activities, such as vasoconstrictor and vasodilatory actions, cell proliferation, pro-fibrosis, neuroendoc

APA, Harvard, Vancouver, ISO, and other styles

16

Langham, Robyn G., and Darren J. Kelly. "Urotensin II and the kidney." Current Opinion in Nephrology and Hypertension 22, no. 1 (2013): 107–12. http://dx.doi.org/10.1097/mnh.0b013e32835b6d57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Thanassoulis, George, Thao Huyhn, and Adel Giaid. "Urotensin II and cardiovascular diseases." Peptides 25, no. 10 (2004): 1789–94. http://dx.doi.org/10.1016/j.peptides.2004.05.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Papadopoulos, Panayiota, Nicolas Bousette, and Adel Giaid. "Urotensin-II and cardiovascular remodeling." Peptides 29, no. 5 (2008): 764–69. http://dx.doi.org/10.1016/j.peptides.2007.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

do Rego, Jean-Claude, Jérôme Leprince, Elizabeth Scalbert, Hubert Vaudry, and Jean Costentin. "Behavioral actions of urotensin-II." Peptides 29, no. 5 (2008): 838–44. http://dx.doi.org/10.1016/j.peptides.2007.12.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bousette, Nicolas, and Adel Giaid. "Urotensin-II and cardiovascular diseases." Current Hypertension Reports 8, no. 6 (2006): 479–83. http://dx.doi.org/10.1007/s11906-006-0026-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

NICHOLLS, H. "Urotensin II in human plasma." Trends in Endocrinology and Metabolism 12, no. 9 (2001): 381–82. http://dx.doi.org/10.1016/s1043-2760(01)00510-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Carotenuto, Alfonso, Paolo Grieco, Ettore Novellino, and Paolo Rovero. "Urotensin-II receptor peptide agonists." Medicinal Research Reviews 24, no. 5 (2004): 577–88. http://dx.doi.org/10.1002/med.20001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Malagon, Maria M., Marcelo Molina, Manuel D. Gahete, et al. "Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5." Peptides 29, no. 5 (2008): 711–20. http://dx.doi.org/10.1016/j.peptides.2007.12.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Loretz, C. A., M. E. Howard, and A. J. Siegel. "Ion transport in goby intestine: cellular mechanism of urotensin II stimulation." American Journal of Physiology-Gastrointestinal and Liver Physiology 249, no. 2 (1985): G284—G293. http://dx.doi.org/10.1152/ajpgi.1985.249.2.g284.

Full text

Abstract:

The Na- and Cl-absorbing goby posterior intestinal epithelium is composed predominantly of mitochondria-rich, tall columnar cells. Glass intracellular microelectrode recording technique was applied to absorptive cells of this relatively leaky epithelium to measure apical cell membrane potential difference (psi mc) and apical membrane fractional resistance. As determined by ion-substitution studies, absorptive cells are characterized by a large, Ba2+-inhibitable apical K conductance, which is a major factor determining psi mc and smaller Cl and Na conductances. Inhibition of the apical Na-Cl-co

APA, Harvard, Vancouver, ISO, and other styles

25

Pavanato, Maria Amália, Bernardo Baldisserotto, Roni João Rakoski, and Olga Martins Mimura. "Transepithelial potential difference of the intestine and gallbladder of Hoplias malabaricus, a freshwater teleost. effect of urotensins I and II." Ciência e Natura 18, no. 18 (1996): 83. http://dx.doi.org/10.5902/2179460x26607.

Full text

Abstract:

This study analyzed the effect of the injection of urotensin I (UI) and urotensis II (UII) on the stabilization of the transepithelial potential difference (TPD) of the medium intestine, rectum, and gallbladder of Hoplias malabaricus to investigate if the transport of ions in these organs is affected "in vivo" by these neurohormones. The TPD of the medium intestine, rectum and gallbladder was serosa positive, and remained constant since the first measurement. The injection of both urotensins did not alter the stabilization of the TPD of the medium intestine and rectum when compared with saline

APA, Harvard, Vancouver, ISO, and other styles

26

Katugampola, S. D., J. J. Maguire, R. E. Kuc, K. E. Wiley, and A. P. Davenport. "Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system." Canadian Journal of Physiology and Pharmacology 80, no. 5 (2002): 369–74. http://dx.doi.org/10.1139/y02-029.

Full text

Abstract:

Using novel synthetic radioligands, we have discovered receptors for the recently paired apelin (APJ orphan receptor), ghrelin (GHS orphan receptor), and urotensin II (orphan GPR14) in the human cardiovascular system and determined their anatomical localisation. In addition, we have established functional vasoactive properties for these three peptides as potential vasoconstrictor/vasodilator mediators and provided evidence for alteration of receptor density in cardiovascular disease. We find that receptors for apelin, ghrelin, and urotensin II are widely distributed in human cardiovascular tis

APA, Harvard, Vancouver, ISO, and other styles

27

Kim, Junghyun, Eunjin Sohn, Chan-Sik Kim, Yun Mi Lee, Kyuhyung Jo, and Jin Sook Kim. "Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–8. http://dx.doi.org/10.1155/2013/547653.

Full text

Abstract:

KIOM-79, a herbal mixture of parched Puerariae radix, gingered Magnoliae cortex, Glycyrrhizae radix, and Euphorbiae radix, has a strong inhibitory effect on advanced glycation end products (AGEs) formation. We investigated the beneficial effects of KIOM-79 on cardiac fibrosis in Zucker diabetic fatty (ZDF) rats. KIOM-79 (50 or 500 mg/kg/day) was orally administered for 13 weeks. AGEs formation and collagen expression in the myocardium were assessed by immunohistochemistry. The expression levels of the receptor for AGEs (RAGE), transforming growth factor-β1 (TGF-β1), collagen IV, fibronectin, u

APA, Harvard, Vancouver, ISO, and other styles

28

Hirose, Takuo, Kazuhiro Takahashi, Nobuyoshi Mori, et al. "Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: Comparison with endothelin-1." Peptides 30, no. 6 (2009): 1124–29. http://dx.doi.org/10.1016/j.peptides.2009.02.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Khan, Kashif, Isabella Albanese, Bin Yu, et al. "Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis." Journal of Thoracic and Cardiovascular Surgery 161, no. 1 (2021): e1-e15. http://dx.doi.org/10.1016/j.jtcvs.2019.09.029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Khan, K., I. Albanese, B. Yu, et al. "UROTENSIN II, UROTENSIN-RELATED PEPTIDE AND THEIR RECEPTOR IN AORTIC VALVE STENOSIS." Canadian Journal of Cardiology 34, no. 10 (2018): S71. http://dx.doi.org/10.1016/j.cjca.2018.07.307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Watanabe, Takuya, Tomoko Kanome, Toshiaki Suguro, and Akira Miyazaki. "Human Urotensin II and Metabolic Syndrome." Vascular Disease Prevention 3, no. 1 (2008): 91–98. http://dx.doi.org/10.2174/1567270000603010015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Watanabe, Takuya, Tomoko Kanome, Toshiaki Suguro, and Akira Miyazaki. "Human Urotensin II and Metabolic Syndrome." Vascular Disease Prevention 3, no. 2 (2006): 91–98. http://dx.doi.org/10.2174/156727006776819396.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Giuliani, L., L. Lenzini, E. Aldighieri, A. C. Pessina, and G. P. Rossi. "Urotensin II is Overexpressed in Pheochromocytoma." High Blood Pressure & Cardiovascular Prevention 14, no. 3 (2007): 145–96. http://dx.doi.org/10.2165/00151642-200714030-00095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Maguire, Janet J., and Anthony P. Davenport. "Is urotensin-II the new endothelin?" British Journal of Pharmacology 137, no. 5 (2002): 579–88. http://dx.doi.org/10.1038/sj.bjp.0704924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Richards, A. Mark, and Chris Charles. "Urotensin II in the cardiovascular system." Peptides 25, no. 10 (2004): 1795–802. http://dx.doi.org/10.1016/j.peptides.2004.04.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Mark Richards, A., M. Gary Nicholls, John G. Lainchbury, Stephen Fisher, and Timothy G. Yandle. "Plasma urotensin II in heart failure." Lancet 360, no. 9332 (2002): 545–46. http://dx.doi.org/10.1016/s0140-6736(02)09709-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Guidolin, Diego, Giovanna Albertin, and Domenico Ribatti. "Urotensin-II as an angiogenic factor." Peptides 31, no. 6 (2010): 1219–24. http://dx.doi.org/10.1016/j.peptides.2010.03.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Jin, Jian, and Stephen A. Douglas. "Non-peptidic urotensin-II receptor modulators." Expert Opinion on Therapeutic Patents 16, no. 4 (2006): 467–79. http://dx.doi.org/10.1517/13543776.16.4.467.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Vaudry, Hubert, Jean-Claude Do Rego, Jean-Claude Le Mevel, et al. "Urotensin II, from fish to human." Annals of the New York Academy of Sciences 1200, no. 1 (2010): 53–66. http://dx.doi.org/10.1111/j.1749-6632.2010.05514.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ong, Kwok-Leung, Bernard M. Y. Cheung, and Karen Siu-Ling Lam. "Urotensin II and the Circulatory System." Hong Kong Journal of Nephrology 7, no. 1 (2005): 9–13. http://dx.doi.org/10.1016/s1561-5413(09)60174-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lehmann, Fredrik, Erika A. Currier, Roger Olsson, Uli Hacksell, and Kristina Luthman. "Isochromanone-based urotensin-II receptor agonists." Bioorganic & Medicinal Chemistry 13, no. 8 (2005): 3057–68. http://dx.doi.org/10.1016/j.bmc.2005.01.056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Zhong, Huan, Yu He, Zhi-Li Tan, and Liang-Ming Liu. "Effect of urotensin II/urotensin II receptor system on autophagy in acute liver failure in mice." World Chinese Journal of Digestology 26, no. 4 (2018): 228. http://dx.doi.org/10.11569/wcjd.v26.i4.228.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Mori, Masaaki, and Masahiko Fujino. "Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain." Peptides 25, no. 10 (2004): 1815–18. http://dx.doi.org/10.1016/j.peptides.2004.06.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Sugo, Tsukasa, Yuko Murakami, Yukio Shimomura, et al. "Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain." Biochemical and Biophysical Research Communications 310, no. 3 (2003): 860–68. http://dx.doi.org/10.1016/j.bbrc.2003.09.102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Hassan, Ghada S., Fazila Chouiali, Takayuki Saito, et al. "Effect of human urotensin-II infusion on hemodynamics and cardiac function." Canadian Journal of Physiology and Pharmacology 81, no. 2 (2003): 125–28. http://dx.doi.org/10.1139/y03-004.

Full text

Abstract:

Recent studies have shown that the vasoactive peptide urotensin-II (U-II) exerts a wide range of action on the cardiovascular system of various species. In the present study, we determined the in vivo effects of U-II on basal hemodynamics and cardiac function in the anesthetized intact rat. Intravenous bolus injection of human U-II resulted in a dose-dependent decrease in mean arterial pressure and left ventricular systolic pressure. Cardiac contractility represented by ±dP/dt was decreased after injection of U-II. However, there was no significant change in heart rate or diastolic pressure. T

APA, Harvard, Vancouver, ISO, and other styles

46

Gong, Hui, Yan-Xia Wang, Yi-Zhun Zhu, et al. "Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat." Journal of Applied Physiology 97, no. 6 (2004): 2228–35. http://dx.doi.org/10.1152/japplphysiol.00540.2004.

Full text

Abstract:

Urotensin II is a cyclic neuropeptide recently shown to play a role via its receptor GPR14 in regulating vascular tone in the mammalian cardiovascular system. The existence of GPR14 in rat heart has been validated by ligand binding assay and RT-PCR. In the present study, we investigated the cellular distribution of GPR14 protein in rat heart by using immunohistochemistry and confocal microscopic immunofluorescence double staining with antipeptide polyclonal antibodies against GPR14 and cell type markers for myocytes and endothelial cells. The direct effect of urotensin II on left ventricular c

APA, Harvard, Vancouver, ISO, and other styles

47

Parmentier, Caroline, Emilie Hameury, Isabelle Lihrmann, et al. "Comparative distribution of the mRNAs encoding urotensin I and urotensin II in zebrafish." Peptides 29, no. 5 (2008): 820–29. http://dx.doi.org/10.1016/j.peptides.2008.01.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Chatenet, David, Christophe Dubessy, Cédric Boularan, et al. "Structure−Activity Relationships of a Novel Series of Urotensin II Analogues: Identification of a Urotensin II Antagonist." Journal of Medicinal Chemistry 49, no. 24 (2006): 7234–38. http://dx.doi.org/10.1021/jm0602110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Boivin, Stéphane, Isabelle Ségalas-Milazzo, Laure Guilhaudis, Hassan Oulyadi, Alain Fournier, and Daniel Davoust. "Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II." Peptides 29, no. 5 (2008): 700–710. http://dx.doi.org/10.1016/j.peptides.2008.02.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Nishi, Mina, Kiyoaki Yonesu, Hideki Tagawa, Mikio Kato, Shinji Marumoto, and Takahiro Nagayama. "A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II–Induced Pressure Response in Mice." Journal of Cardiovascular Pharmacology 73, no. 1 (2019): 15–21. http://dx.doi.org/10.1097/fjc.0000000000000618.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!